poisar

Stock

Janux Therapeutics, Inc. JANX

$16.08+0.50%

Overview

JANX market data

Price History

JANX price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.83
Diluted earnings per share over the trailing twelve months.
Beta
2.39
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-294.4%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$12.12 – $35.34
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $978.2M · P/B 3.02 · P/S 40.76.

Company News

4 captured
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55Benzinga · Aug 7, 2026, 5:00 PM
Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M EstimateBenzinga · Aug 6, 2026, 10:06 PM
Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26Benzinga · Jun 25, 2026, 2:15 PM
8-K filing — Janux Therapeutics, Inc. (JANX)SEC EDGAR · Jun 23, 2026, 8:05 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock